Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective.
| Autor: | Levy P; Université Paris-Dauphine, Université PSL, LEDA, [LEGOS], Paris, France., Lemański T; Health Economics and Outcomes Research, Putnam, Kraków, Poland., Crossan C; Health Economics and Outcomes Research, Putnam, London, UK., Lefebvre A; Global Value & Access and Pricing, Servier Group, Suresnes, France., Brière JB; Global Value & Access and Pricing, Servier Group, Suresnes, France., Degli Esposti L; CliCon S.r.l. Società Benefit, Health, Economics and Outcomes Research, Bologna, Italy., Khan ZM; Zebgene LLC, Malvern, PA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Oct; Vol. 24 (8), pp. 967-975. Date of Electronic Publication: 2024 Jun 14. |
| DOI: | 10.1080/14737167.2024.2365988 |
| Abstrakt: | Objective: To evaluate the cost-effectiveness of a single-pill combination (SPC) of perindopril/amlodipine/indapamide versus its free equivalent combination (FEC) in adults with hypertension in Italy. Methods: A Markov model was developed to perform a cost-utility analysis with a lifetime horizon and an Italian healthcare payer's perspective. In the model, the additional effect of the SPC on blood pressure level compared with the FEC was translated into a decreased risk of cardiovascular events and CKD, which was modeled via Framingham risk algorithms. Difference in persistence rates of SPC and FEC were modeled via discontinuation rates. Results: A perindopril/amlodipine/indapamide SPC is associated with lower cost and better health outcomes compared to its FEC. Over a lifetime horizon, it is associated with a 0.050 QALY gain and cost savings of €376, resulting from lower cardiovascular event rates. In the alternative scenario, where different approach for modeling impact of adherence was considered, incremental gain of 0.069 QALY and savings of €1,004 were observed. Results were robust to sensitivity and scenario analyses, indicating that use of this SPC is a cost-effective strategy. Conclusions: The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|